KR101512495B1 - 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 - Google Patents

혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 Download PDF

Info

Publication number
KR101512495B1
KR101512495B1 KR1020137011283A KR20137011283A KR101512495B1 KR 101512495 B1 KR101512495 B1 KR 101512495B1 KR 1020137011283 A KR1020137011283 A KR 1020137011283A KR 20137011283 A KR20137011283 A KR 20137011283A KR 101512495 B1 KR101512495 B1 KR 101512495B1
Authority
KR
South Korea
Prior art keywords
bone marrow
group
delete delete
actigenine
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137011283A
Other languages
English (en)
Korean (ko)
Other versions
KR20130093125A (ko
Inventor
쯔콴 자오
Original Assignee
루난 파마슈티컬 그룹 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루난 파마슈티컬 그룹 코퍼레이션 filed Critical 루난 파마슈티컬 그룹 코퍼레이션
Publication of KR20130093125A publication Critical patent/KR20130093125A/ko
Application granted granted Critical
Publication of KR101512495B1 publication Critical patent/KR101512495B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137011283A 2010-10-08 2011-10-08 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 Active KR101512495B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010299279.X 2010-10-08
CN201010299279.XA CN102440986B (zh) 2010-10-08 2010-10-08 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
PCT/CN2011/080543 WO2012045282A1 (zh) 2010-10-08 2011-10-08 牛蒡子苷元在制备预防或治疗血细胞减少相关疾病的药物中的用途

Publications (2)

Publication Number Publication Date
KR20130093125A KR20130093125A (ko) 2013-08-21
KR101512495B1 true KR101512495B1 (ko) 2015-04-15

Family

ID=45927226

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137011283A Active KR101512495B1 (ko) 2010-10-08 2011-10-08 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도

Country Status (7)

Country Link
US (1) US20130190394A1 (enExample)
EP (1) EP2626071B1 (enExample)
JP (1) JP5744213B2 (enExample)
KR (1) KR101512495B1 (enExample)
CN (2) CN102440986B (enExample)
AU (1) AU2011313667B2 (enExample)
WO (1) WO2012045282A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397547B (zh) * 2010-09-19 2013-06-12 山东新时代药业有限公司 一种抗癌药物组合物
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途
CN103027906B (zh) * 2011-10-08 2015-11-11 鲁南制药集团股份有限公司 牛蒡子苷元在治疗贫血疾病中的应用
JP5707534B2 (ja) * 2012-03-26 2015-04-30 クラシエ製薬株式会社 抗癌剤
CN103446100A (zh) * 2012-05-29 2013-12-18 鲁南制药集团股份有限公司 牛蒡子苷元的舌下含服制剂
JP5696191B2 (ja) * 2013-04-27 2015-04-08 クラシエ製薬株式会社 抗癌幹細胞剤
CN104546823B (zh) * 2013-10-21 2019-08-30 鲁南制药集团股份有限公司 淫羊藿苷元在制备治疗或预防血小板减少症药物中的用途
JP6294476B2 (ja) * 2013-10-21 2018-03-14 ▲魯▼南制▲薬▼集▲団▼股▲フン▼有限公司 血球減少を予防又は治療するための薬物の製造におけるアンヒドロイカリチンの使用
US9907852B2 (en) 2014-04-10 2018-03-06 National University Corporation University Of Toyama Anticancer agent and side-effect-alleviating agent
JP6197077B1 (ja) * 2016-07-14 2017-09-13 クラシエ製薬株式会社 抗癌剤、放射線増感剤および食品組成物
CN110623960B (zh) * 2018-06-22 2022-08-19 成都山权江生物科技有限公司 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
JP7675547B2 (ja) * 2021-04-01 2025-05-13 クラシエ株式会社 酸化ｌｄｌ増加抑制剤および酸化ｌｄｌ増加抑制用食品組成物
CN119462619B (zh) * 2024-11-06 2025-10-24 浙江大学 一种橙酮类化合物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560265A (zh) * 2004-02-26 2005-01-05 广州中医药大学 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP2009523805A (ja) * 2006-01-17 2009-06-25 シグナル ファーマシューティカルズ，エルエルシー ＴＮＦα、ＰＤＥ４及びＢ−ＲＡＦの阻害剤、それらの組成物及びそれらの使用法
CN101036643A (zh) * 2006-03-13 2007-09-19 海南盛科天然药物研究院有限公司 含牛蒡子苷元的药物组合物及其制备方法
CN101134031B (zh) 2006-08-30 2012-05-09 山东绿叶天然药物研究开发有限公司 牛蒡子苷元在制备治疗或预防慢性肾功能衰竭及肾纤维化的药物中的用途
CN102210653B (zh) * 2010-04-03 2014-06-04 鲁南制药集团股份有限公司 牛蒡苷元的微乳制剂
CN102440986B (zh) * 2010-10-08 2014-12-03 鲁南制药集团股份有限公司 牛蒡子苷元在制备防治辐射或化学品引起的骨髓抑制的药物中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560265A (zh) * 2004-02-26 2005-01-05 广州中医药大学 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法

Also Published As

Publication number Publication date
CN103209693A (zh) 2013-07-17
AU2011313667A1 (en) 2013-05-02
WO2012045282A1 (zh) 2012-04-12
JP5744213B2 (ja) 2015-07-08
US20130190394A1 (en) 2013-07-25
EP2626071B1 (en) 2016-01-13
JP2013542205A (ja) 2013-11-21
CN102440986B (zh) 2014-12-03
EP2626071A1 (en) 2013-08-14
HK1188122A1 (en) 2014-04-25
CN102440986A (zh) 2012-05-09
CN103209693B (zh) 2015-10-07
KR20130093125A (ko) 2013-08-21
AU2011313667B2 (en) 2015-08-27
EP2626071A4 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
KR101512495B1 (ko) 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도
US10799521B2 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
JP2016534074A5 (enExample)
SG186999A1 (en) Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment
US20210030678A1 (en) Cannabinoid and cbd liposome formulations and uses thereof
CN104688722B (zh) 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途
KR100310979B1 (ko) 간질환 예방 및 치료용 생약조성물
CN109731019B (zh) 一种具有化疗增效作用的组合物，包括组成、制备及应用
AU2018348892B2 (en) Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof
CN101269063A (zh) 表没食子儿茶素没食子酸酯在制备具有预防和治疗人乳腺癌症的产品中的应用
CN102178679A (zh) 吡咯喹啉醌在恢复放射后骨髓造血功能中的应用
CN100563647C (zh) 灯盏花和丹参酮ⅱa磺酸钠的药用组合物
WO2015073958A1 (en) Ephedra alata extracts and methods of use thereof
CN110151824A (zh) 一种治疗下咽癌的药物组合物及其制备方法
CN110063988A (zh) 一种治疗神经母细胞瘤的药物组合物及其制备方法
CN1320440A (zh) 大花红景天有效成分制剂及制备方法
WO2006029550A1 (fr) Melange hemostatique constitue de feuilles de patates douces, procedes de preparation et d'utilisation correspondants
CN102416017A (zh) 药用层孔菌中三种单体化合物的抗肿瘤活性及其在医药中的应用
HK1188122B (en) Arctigenin for use in preventing or treating bone marrow suppression
CN118370743A (zh) 紫苏醛在制备治疗产后缺乳的药物中的用途
CA2297933A1 (en) A method to improve immune function
CN110354168A (zh) 一种治疗肾透明细胞癌的药物组合物及其制备方法
CN108991453A (zh) 一种复方纳米蜂胶的制备方法及其产品
CN110354170A (zh) 一种治疗甲状腺癌的药物组合物及其制备方法
CN103432134A (zh) 升高白细胞及治疗再生障碍性贫血的异粉防己碱药物及其制剂

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20130430

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130430

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141001

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150223

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150409

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150410

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180326

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180326

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200325

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210325

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240404

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250403

Start annual number: 11

End annual number: 11